L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma

Bu, Shi; Yuan, Fangfang; Wei, Xudong; Yin, Qingsong; Li, Yufu; Mi, Ruihua; Yang, Haiping; Li, Hongyi; Ge, Shoubei; Liu, Yanyan; Song, Yongping

doi:10.3892/etm.2016.3249

Cited by 13 publications

(8 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis evaluating the use of L-asparaginase showed that the objective and complete response rates were both improved with the addition of this drug [ 24 ] in regimens such as SMILE (steroid (dexamethasone), methotrexate, ifosfamide, L-asparaginase, and etoposide) at over 50% [ 25 ] and GELOX (gemcitabine, L-asparaginase, and oxaliplatin) at over 70% ( Table 1 ) [ 26 ]. The widespread use of L-asparaginase-based regimens in combination with cytotoxic chemotherapy agents that are not P-glycoprotein substrates has improved survival, although long-term outcomes remain inadequate [ 27 ]. In addition, radiotherapy plays an important role for the treatment of limited stage disease [ 28 ].…”

Section: Current Standard Therapy: Cytotoxic Chemotherapy and Radiationmentioning

confidence: 99%

Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions

Reneau

Shindiapina

Braunstein

et al. 2022

JCM

View full text Add to dashboard Cite

Extranodal natural killer/T(NK/T)-cell lymphoma (ENKTL) is a rare subtype of non-Hodgkin lymphoma that typically presents with an isolated nasal mass, but a sizeable minority present with advanced stage disease and have a significantly poorer prognosis. Those with limited disease are standardly treated with chemotherapy and radiation while those with advanced stage disease are treated with L-asparaginase containing chemotherapy regimens. The addition of modern radiation therapy techniques and the incorporation of L-asparaginase into chemotherapy regimens have significantly improved outcomes in this disease, but relapses and death from relapsed disease remain frequent. Given the high rate of relapse, several novel therapies have been evaluated for the treatment of this disease. In this review, we explore the current standard of care for ENKTL as well as novel therapies that have been evaluated for its treatment and the biologic understanding behind these therapies.

show abstract

Section: Current Standard Therapy: Cytotoxic Chemotherapy and Radiationmentioning

confidence: 99%

Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions

Reneau

Shindiapina

Braunstein

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…There are studies in cancer cells showing the requirement of asparagine for cellular adaptation during glutamine starvation and for nucleotide biosynthesis (Zhang et al, 2014;Zhu et al, 2017). Furthermore, asparaginase, an enzyme that catalyzes asparagine into aspartate and ammonia, has been used to treat cancers including acute lymphoblastic leukemia, acute myeloid leukemia and non-Hodgkin's lymphoma (Hettmer et al, 2015;Bu et al, 2016;Egler et al, 2016). However, asparaginase resistance is reported in some cases of cancers and the use of ASNS inhibitors has been proposed and is currently in the development process (Gutierrez et al, 2006).…”

Section: Systematic Identification Of Novel Host-virus Interactions Umentioning

confidence: 99%

Systems Virology and Human Cytomegalovirus: Using High Throughput Approaches to Identify Novel Host-Virus Interactions During Lytic Infection

Lee

Grey

2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Human Cytomegalovirus (HCMV) is a highly prevalent herpesvirus, persistently infecting between 30 and 100% of the population, depending on socioeconomic status (Fields et al., 2013). HCMV remains an important clinical pathogen accounting for more than 60% of complications associated with solid organ transplant patients (Kotton, 2013; Kowalsky et al., 2013; Bruminhent and Razonable, 2014). It is also the leading cause of infectious congenital birth defects and has been linked to chronic inflammation and immune aging (Ballard et al., 1979; Griffith et al., 2016; Jergovic et al., 2019). There is currently no effective vaccine and HCMV antivirals have significant side effects. As current antivirals target viral genes, the virus can develop resistance, reducing drug efficacy. There is therefore an urgent need for new antiviral agents that are effective against HCMV, have better toxicity profiles and are less vulnerable to the emergence of resistant strains. Targeting of host factors that are critical to virus replication is a potential strategy for the development of novel antivirals that circumvent the development of viral resistance. Systematic high throughput approaches provide powerful methods for the identification of novel host-virus interactions. As well as contributing to our basic understanding of virus and cell biology, such studies provide potential targets for the development of novel antiviral agents. High-throughput studies, such as RNA sequencing, proteomics, and RNA interference screens, are useful tools to identify HCMV-induced global changes in host mRNA and protein expression levels and host factors important for virus replication. Here, we summarize new findings on HCMV lytic infection from high-throughput studies since 2014 and how screening approaches have evolved.

show abstract

“…Basic systemic treatment for ENKTCL is unique in the context of PTCL being permanently diverted to L-Aspa based induction regimens. This is primarily because of the documented L-Aspa superiority over anthracycline-based regimens which are inefficient in long-term disease control (62)(63)(64)(65)(66).…”

Section: Management (Upfront and Relapse Setting) For Extranodal Entimentioning

confidence: 99%

Nodal and extranodal peripheral T/NK-cell neoplasms: Current aspects

Petković¹,

Popović²,

Džunić³

et al. 2020

Acta fac medic Naissensis

View full text Add to dashboard Cite

Peripheral T/NK-cell lymphomas (PTCL) are rare, bizarre, and extremely diverse cancers. The disease is prone to relapse with a high level of chemorefractoriness leading to a poor outcome. Almost 70% of patients will experience relapse, with a median 5-year overall survival (OS) in approximately 30%. Upfront management of PTCL has been extrapolated from the treatment paradigm for aggressive B-NHL. However, universally accepted induction is rather palliative than curative. Regardless of the maximal reinforcement of upfront management, only event-free survival has been influenced but not the OS. All actual guidelines emphasize the importance of the autologous stem cell transplantation (auto-SCT) as a consolidation of first major response. The allogeneic SCT (allo-SCT) is not evidence-based part of upfront management. Nevertheless, its use is justified in the relapsed/refractory setting. Unfortunately, the vast majority of patients are not candidates for aggressive treatment modalities making the recommended paradigm as limited feasible. Regarding such a situation, novel compounds are warranted. Although presented data indicate ominous prognosis in PTCL, it is important to denote that there has been evidence-based improvement in the treatment paradigm by the introduction of L-Asparaginase and targeted therapy for CD30+ PTCL. In this sense, a considerable number of new compounds entered early phase trials and gave promising results. All lights have been focused on upcoming results given the fact that at the moment we have not much to offer to the patients who have relapsed or were primary refractory.

show abstract

L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma

Cited by 13 publications

References 43 publications

Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions

Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions

Systems Virology and Human Cytomegalovirus: Using High Throughput Approaches to Identify Novel Host-Virus Interactions During Lytic Infection

Nodal and extranodal peripheral T/NK-cell neoplasms: Current aspects

Contact Info

Product

Resources

About